Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy

Ichiro Maruko*, Hideki Koizumi*, Taiji Hasegawa*, Hisaya Arakawa*, Tomohiro Iida*

Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Shinjuku, Tokyo, Japan

These authors contributed equally to this work.

*imaruko@twmu.ac.jp

Abstract

Purpose
To compare the efficacy of the subthreshold micropulse laser (SML) to conventional laser (CL) in treating focal leakages of the retinal pigment epithelium (RPE) in the eyes with central serous chorioretinopathy (CSC).

Methods
Twenty-nine eyes of 28 patients with CSC and typical focal leakage were treated with CL or SML. Both treatments were made with a 577 nm yellow laser (CL: NIDEK MC-500, SML: IRIXIDE IQ577). The percentage of eyes with a complete resolution, the distance of the laser burns from the fovea, and injury of the RPE after treatment were studied.

Results
A complete resolution was seen in 10 of 15 eyes (66.7%) after CL and 9 of 14 eyes (64.3%) after SML (P = 0.89). The average distance from the foveal center to the leakage point was 1282±596 μm for eyes treated with CL and 1271±993 μm for eyes treated with SML (P = 0.4). Only three eyes treated with SML had treatment sites within 500 μm of the fovea. RPE damage determined by fundus autofluorescence was found in all eyes treated with CL and only one eye treated with SML (P<.01).

Conclusions
SML achieved equivalent therapeutic effects as CL but without RPE damage in eyes with CSC.
NIDEK Co., Ltd., outside the submitted work. Dr. Koizumi reports grants and personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Santen Pharmaceutical Inc., personal fees from Alcon Japan, Ltd., personal fees from Topcon Co., Ltd., personal fees from Senju Pharmaceutical Co., Ltd., personal fees from HOYA Corp., personal fees from Canon Inc., personal fees from Wakamoto Pharmaceutical Co., Ltd., personal fees from NIDEK Co., Ltd., outside the submitted work. Dr. Hasegawa has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Iida reports grants and personal fees from Novartis Pharma K.K. (Japan), personal fees from Bayer Yakuhin, Ltd. (Japan), grants and personal fees from Santen Pharmaceutical Co., Ltd. (Japan), grants from Nidek, support research from Chuo-sangyo (Japan), outside the submitted work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Dr. Maruko reports grants from JSPS KAKENHI (Grant Number JP16K11274), grants and personal fees from Novartis Pharma K.K., personal fees from Bayer Cover Letter Yakuhin, Ltd., personal fees from Santen Pharmaceutical Inc., personal fees from Alcon Japan, Ltd., personal fees from Topcon Co., Ltd., personal fees from Senju Pharmaceutical Co., Ltd., personal fees from NIDEK Co., Ltd., outside the submitted work. Dr. Koizumi reports grants and personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Santen Pharmaceutical Inc., personal fees from Alcon Japan, Ltd., personal fees from Topcon Co., Ltd., personal fees from Senju Pharmaceutical Co., Ltd., personal fees from HOYA Corp., personal fees from Canon Inc., personal fees from Wakamoto Pharmaceutical Co., Ltd., personal fees from NIDEK Co., Ltd., outside the submitted work. Dr. Hasegawa has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Iida reports grants and personal fees from Novartis Pharma K.K. (Japan), personal fees from Bayer Yakuhin, Ltd. (Japan), grants and personal fees from Santen Pharmaceutical Co., Ltd. (Japan), grants from Nidek, support research from Chuo-sangyo (Japan), outside the submitted work. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Introduction

Central serous chorioretinopathy (CSC) is characterized by an idiopathic serous retinal detachment (SRD) in the posterior pole associated with focal or diffuse leakage from the retinal pigment epithelium (RPE).[1] Some of the SRDs resolve spontaneously, and the vision is generally good. However, recurrent or persistent cases of CSC can cause visual reductions.[2–4] Although laser treatment to the focal leakage sites is still a standard therapy for such cases,[5–7] this method is difficult to implement in eyes with leakage sites within or very close to the foveal avascular zone (FAZ). The difficulty is because conventional laser (CL) treatments usually leave atrophic scars of varying sizes on the RPE.

Recently, subthreshold laser treatments were reported to be effective in treating eyes with CSCs.[8–12] Several reports have compared the efficacies of the different treatments for CSC including subthreshold laser treatments, CL, photodynamic therapy, and intravitreal injections of anti-vascular endothelial growth factor.[13,14] However, there is no study comparing CL treatments to subthreshold micropulse laser (SML) treatments on the complete resolution of the CSC and RPE damages.

Thus, the purpose of this study was to compare the efficacy of SML to CL for the treatment of focal leakages of the RPE in eyes with CSC.

Materials and methods

This was a retrospective study conducted according to the tenets of the Declaration of Helsinki. The Institutional Review Board of the Tokyo Women’s Medical University School of Medicine approved the study which included the use of optical coherence tomography (OCT) and fundus autofluorescence (FAF) on eyes with macular and retinal disorders, observational study of age-related macular degeneration, and similar disorders including CSC. In our institution, a consent form is not required for a retrospective study.

Twenty-nine eyes of twenty-eight patients (20 men, 8 women; average age, 48.4 years) with CSC and typical focal leakage of more than 3-months duration were studied. The eyes were treated with CL or SML from November 2015 to October 2016. Because SML therapy was introduced in our hospital in May 2016, CL was performed until April 2016, and SML was conducted from May 2016.

The clinical examinations used to diagnose CSC included measurements of the best-corrected visual acuity (BCVA), slit-lamp biomicroscopy with and without a contact lens, indirect ophthalmoscopy, and digital fluorescein and indocyanine green angiography (HRA2, Heidelberg Engineering, Heidelberg, Germany). The BCVA was measured with a Japanese standard visual acuity chart, and the decimal BCVA was converted to the logarithm of the minimum angle of resolution (logMAR) units for the statistical analyses.

All eyes were examined by swept source OCT (DRI-OCT Atlantis, Topcon, Tokyo, Japan) to evaluate the SRD. The central retinal thickness and subfoveal choroidal thickness were measured using the caliper tool in the OCT software before and after the treatment. The thicknesses of the retina was defined as the distance from the inner limiting membrane to the inner RPE surface including SRD, and the choroidal thickness as the distance between the outer RPE surface and the inner scleral surface.

CSC was diagnosed to be present if the eye had subretinal fluid involving the macula that was associated with idiopathic leaks from the RPE detected during fluorescein angiography. Only eyes with CSC and typical focal leakage of more than 3-months duration were included in this study. Thus, eyes with the chronic type of CSC with diffuse leakage were excluded because of difficulty in identifying the treatment sites. The distance between the leakage point and the foveal center was measured in the early phase of fluorescein angiography. Indocyanine...
green angiography was used to confirm the presence of choroidal vascular hyperpermeability, and to rule out the presence of choroidal neovascularization including polypoidal choroidal vasculopathy.

All patients had a reduction of the visual acuity, and they agreed to the laser treatment after being informed of the risks and benefits. The duration of the SRD was estimated from the patient’s recall of the onset of the visual symptoms.

CL was performed with a 577 nm yellow laser (NIDEK MC-500, Nidek, Gamagori, Japan) with a 200 μm spot diameter, a 0.20 sec duration, and 60–80 mW power. The endpoint of CL photocoagulation was the production of a slight graying of the RPE. SML photocoagulation was performed with a 577 nm micropulse yellow laser (IRIDEX IQ577) with a 200 μm spot diameter, a 0.20 sec duration with 15% duty cycle (D/C), and 140–200 mW power. The actual laser power for the SML treatment was determined by the visible laser scar of a trial photocoagulation created with continuous wave laser energy for 0.1 s with a diameter of 200 μm outside the vascular arcade without a SRD. About 70–100 mW power with a continuous wave laser was enough to develop a graying of the RPE. Thereafter, laser spots were applied using a 15% duty cycle micropulse mode at 200% of the threshold energy for 0.20 sec which delivered 60% of the threshold energy.[15] The number of SML applications in one session was limited to 10 shots because the laser scars were not visible. The RPE changes after the treatment with CL or SML were also analyzed by FAF (CX-1 MYD/NM, Canon, Japan).

The percentage of eyes with a complete resolution, the distance between the leakage points and the foveal center, the frequency of the treatments, the changes in the BCVA, the subfoveal choroidal thickness, and the RPE damage after treatment were studied.

All P-values were two-sided and a P < 0.05 was considered statistically significant in Mann-Whitney U test and the Wilcoxon signed-rank test. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).[16] More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics.

Results

CL treatment was performed on 15 eyes of 14 patients (9 men, 5 women; average age, 49.9 years) from November 2015 to April 2016, and SML treatment was performed on 14 eyes of 14 patients (11 men, 3 women; average age, 46.9 years) from May 2016 to October 2016. There were no significant differences in the duration of the symptoms between the two groups. The baseline characteristics, the resolution of the SRD, the number of treatments, the BCVA before and after treatment, the central retinal thickness before and after treatment, the subfoveal choroidal thickness before and after treatment were summarized in Table 1.

The SRD was resolved in 10 of 15 eyes (66.7%) after CL and 9 of 14 eyes (64.3%) after SML (P = 0.89). The time to resolution of the SRD was 3.3 months after CL and 1.9 months after SML (P = 0.16, Mann Whitney U-test). The average follow-up period was 3.4 months after CL and 2.2 months after SML (P = 0.74, Mann Whitney U-test). The average number of treatments was 1.13 for CL and 1.34 for SML (P = 0.31, Mann Whitney U-test).

The mean decimal BCVA was 0.92 at the baseline and 0.95 after CL. For the SML group, the mean decimal BCVA was 0.96 at the baseline and 0.94 after the treatment. None of these differences in the BCVA was significant (both CL and SML, P > 0.1, Wilcoxon signed-rank test).

The mean central retinal thickness before treatment was 338 ± 135 μm in the CL group and 328 ± 129 μm in the SML group (P = 0.83, Mann Whitney U-test). The mean central retinal thickness after treatment was 173 ± 37 μm in the CL group and 192 ± 64 μm in the SML group.
group \( (P = 0.78, \text{Mann Whitney U-test}) \). There was a significant difference between the central retinal thickness before and after treatment in both the CL and SML groups \( (P < 0.01, \text{Wilcoxon signed-rank test}) \). The mean subfoveal choroidal thickness before treatment was 433 ± 89 \( \mu \text{m} \) in the CL group and 411 ± 106 \( \mu \text{m} \) in the SML group \( (P = 0.56, \text{Mann Whitney U-test}) \). The mean subfoveal choroidal thickness after treatment was 423 ± 91 \( \mu \text{m} \) in the CL group and 420 ± 106 \( \mu \text{m} \) in the SML group \( (P = 0.98, \text{Mann Whitney U-test}) \). There was no significant difference between the choroidal thicknesses before and after treatment in both CL \( (P = 0.13, \text{Wilcoxon signed-rank test}) \) and SML \( (P = 0.45, \text{Wilcoxon signed-rank test}) \) groups.

The mean distance between the leakage site and the foveal center was 1282 ± 596 \( \mu \text{m} \) (range, 539–2498 \( \mu \text{m} \) for the CL treatment group and 1271 ± 993 \( \mu \text{m} \) (range, 310–3498 \( \mu \text{m} \) for the SML treatment group \( (P = 0.4, \text{Mann Whitney U-test}) \). There were 4 eyes (26.7\%) treated with CL and 7 eyes (50.0\%) treated with SML where the leakage sites were within 1000 \( \mu \text{m} \) of the foveal center. Three of 7 eyes in the SML group had treatment sites within 500 \( \mu \text{m} \) of the fovea. \((\text{Table 2})\)

The changes in the RPE were evaluated by FAF before and after treatment in the eyes with complete resolution excluding one eye of a SML cases without FAF images before treatment. RPE damage was observed in 10 of 10 eyes \((\text{Fig 1})\) in the CL treated group and 1 of 9 eyes \((12.5\%, \text{Fig 2})\) in the SML treated group \( (P < 0.01) \). A 32-year-old man with SRD due to CSC was treated twice with SML, and the second session was performed with the maximum

### Table 1. Baseline background and post treatment characteristics in the eyes with conventional laser and subthreshold micropulse laser treatments.

| Treatment | n   | Symptom (M) | Complete Resolution | F/U (M) | Treatment Frequency | BCVA (snellen) | CRT ± SD (µm) | SCT ± SD (µm) |
|-----------|-----|-------------|---------------------|---------|--------------------|----------------|---------------|---------------|
|           |     |             |                     |         |                    | Before | After | Before | After | Before | After |
| CL        | 15  | 3.1         | 10 (66.7\%)         | 3.4     | 1.13               | 0.92  | 0.94  | 338±135 | 173±37 | 433±89 | 423±91 |
| SML       | 14  | 2.4         | 9 (64.3\%)          | 2.2     | 1.36               | 0.96  | 0.94  | 328±129 | 192±64 | 411±106 | 420±106 |
| Diff (P-value) |  | no (0.28) | no (0.89) | no (0.74) | no (0.31) | no (0.45) | no (0.45) | no (0.83) | no (0.78) | no (0.56) | no (0.98) |

BCVA = best-corrected visual acuity  
SD = standard deviation  
CL = conventional laser  
SML = subthreshold micropulse laser  
Symptom (M) = subjective symptom duration (months)  
F/U (M) = follow-up periods or time to resolution (months)  
CRT = central retinal thickness  
SCT = subfoveal choroidal thickness  
Diff = significant differences between CL and SML

### Table 2. Distance between leak point and foveal center in the eyes with conventional laser and subthreshold micropulse laser treatments.

| Treatment | Distance ± SD | 500–1000 µm | ≤500 µm |
|-----------|---------------|-------------|--------|
| CL        | 1282±596      | 4           | 0      |
| SML       | 1271±993      | 4           | 3      |

Distance = mean distance between leak point and foveal center  
SD = standard deviation  
CL = conventional laser  
SML = subthreshold micropulse laser

https://doi.org/10.1371/journal.pone.0184112.t001

https://doi.org/10.1371/journal.pone.0184112.t002
Discussion

Our findings showed that SML treatment was almost as effective as CL treatment for the eyes with CSC. Although CL treatment left permanent scar in all eyes, SML caused almost no RPE damage as determined by FAF in the eyes with a complete resolution.

CL photocoagulation is still one of the standard therapies for CSC, however it is not possible to treat leakages within or close to the FAZ because an RPE scar remains after the treatment. Photodynamic therapy (PDT) is an option not only for chronic CSC with diffuse leakage but also for acute CSC with leakage within or close to the FAZ.[17–20] PDT has not been approved for CSC, and it is not a standard therapy. In contrast, SML is expected to be accepted for CSC with leakage within the FAZ because SML does not cause RPE scars. Elhamid et al.[8] reported number of 200 mW pulses (D/C 15%) with the same SML parameters except for the laser power. In only one case, FAF showed that the RPE was damaged at the sites of the second SML session (Fig 2, Case 6).

Fig 1. Changes in the fundus autofluorescence before and after conventional laser (CL) treatment in 10 eyes with central serous chorioretinopathy. Retinal pigment epithelial damage was observed in 10 of the 10 eyes (white arrows) after the CL treatment.

https://doi.org/10.1371/journal.pone.0184112.g001
on the efficacy of SML in 15 eyes with CSC including 9 eyes with leakage within the FAZ. They had a complete resolution in 73% of the eyes. In our study, we successfully treated 3 eyes with leakage within 500 μm of the fovea although we did not treat eyes with leakages within the FAZ. These results suggest that SML can be safely used for CSC even on leakages close to the foveal center. However, further studies are needed to determine whether SML treatment within the FAZ should be considered.

CL usually uses continuous-wave lasers for the photocoagulation, and the heat it generates affects not only the targeted RPE cells but also the surrounding areas. This then causes RPE scars larger than expected, and the expansion of laser scars is called "atrophic creep" after laser photocoagulation. On the other hand, SML generates less heat. This then leads to less damage of the targeted RPE and the surrounding areas than CL.

RPE damage was not observed in the cases with SML treatment except for one case. We treated a recurrent case with a second session of SML with 200 mW (D/C 15%), and RPE scars developed at the sites of the applications. Thus, there is a limit in the use of SML. It is necessary to be careful even for SML treatments especially the laser power.

Lanzetta et al.[9] and Chen et al.[10] also used SML with an 810-nm laser, and they reported a complete resolution in 71% and 55% respectively. Yadav et al.[11] treated 15 eyes with chronic CSC with a 577-nm laser, but they reported only 40% of the eyes had a complete resolution. Sholz et al.[12] in their large comparison study between SML and half-dose PDT for chronic CSC reported a complete resolution in 36% of the SML group with a 577-nm laser.
during 6 weeks follow-up period. Our results were better with a complete resolution in about 65%, which may because our cases include the eyes without the diffuse leakage but only with the typical focal leakage.

There have been reports on the benefits of SML treatment compared with alternative treatments.[13, 14] The effects of SML on chronic CSC should be compared with that of PDT. In fact, Sholz et al. described the superiority of SML to half-dose PDT for chronic CSC. In another report, Özımert et al.[21] reported that the results of SML was as good as that of PDT for chronic CSC with durations of more than 6 months. Koss et al.[22] reported that SML reduced the leakage more than intravitreal bevacizumab injections. SML might be the new standard treatment for CSC.

This retrospective study had several weaknesses including the small sample size and short follow-up periods. In addition, it was difficult to completely determine whether the results were due to the treatment or spontaneous resolution although it was unlikely that cases that did not recover spontaneously for more than 3 months might recover at this high rate in both groups. In addition, this was not a truly comparative study because the study time periods were different. There might also have been a selection bias for the eyes with leakages closer to fovea because no RPE scar remained in most of the SML cases.

In conclusion, the results showed that SML was as effective as CL in eyes with typical CSC. In addition, RPE damage was found significantly more frequently after CL than after SML. SML treatment within FAZ may also be considered as the results. However, it will be necessary to obtain data from a larger number of patients including those with chronic CSC to demonstrate the complete safety of SML especially for eyes with leakages close to the FAZ.

Supporting information
S1 Table. Baseline characteristics and changes before and after treatment in all data.

(DOCX)

Acknowledgments
The authors thank Professor Emeritus Duco Hamasaki of the Bascom Palmer Eye Institute, University of Miami, for his critical discussion and editing of the final manuscript.

Author Contributions
Conceptualization: Ichiro Maruko.
Data curation: Ichiro Maruko, Hideki Koizumi, Taiji Hasegawa, Hisaya Arakawa.
Supervision: Tomohiro Iida.
Writing – original draft: Ichiro Maruko.
Writing – review & editing: Ichiro Maruko, Hideki Koizumi, Taiji Hasegawa, Hisaya Arakawa, Tomohiro Iida.

References
1. Klais CM, Ober MD, Ciardella AP, Yannuzzi LA. Central serous chorioretinopathy. In Ryan SJ, ed-in-chief, Hinton DR, Schachat AP, Wilkinson CP, eds. Retina. 4th ed. vol. 2. Philadelphia, PA: Elsevier Mosby; 2006. pp 1135–1161
2. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967 Mar; 63(3):Suppl.1–139.
3. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988 Nov; 72(11):829–834. PMID: 3061449

4. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996 Jun; 114(6):689–692. PMID: 8639079

5. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr; 95(4):457–466. PMID: 6682293

6. Gartner J. Long-term follow-up of an ophthalmologist’s central serous retinopathy, photoacoagulated by sungazing. Doc Ophthalmol. 1987 May; 66(1):19–33. PMID: 3428072

7. Lim JJ. Iatrogenic choroidal neovascularization. Surv Ophthalmol. 1999 Sep-Oct; 44(2):95–111. PMID: 10541149

8. Elhamid AHA. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin Ophthalmol. 2015 Dec 3; 9:2277–2283. https://doi.org/10.2147/OPTH.S87499 PMID: 26664043

9. Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy: A pilot study. Eur J Ophthalmol. 2008 Nov-Dec; 18(6):934–940. PMID: 18988165

10. Chen SN, Hwang-JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtapfoveal leakage. Ophthalmology. 2008 Dec; 115(12):2229–2234. https://doi.org/10.1016/j.ophtha.2008.06.026 PMID: 19041477

11. Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dairi S, et al. Continuing medical education: subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Lond). 2015 Feb; 29(2):258–264.

12. Scholz P, Altay L, Fauser S. Comparison of sub-threshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond). 2016 Oct; 30(10):1371–1377.

13. Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Cochrane Database Syst Rev. 2015 Dec 22; (12).

14. Scholz P, Altay L, Fauser S. A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Adv Ther Adv Ther. 2017 Jul; 34(7):1528–1555. https://doi.org/10.1007/s12325-017-0559-y PMID: 28540655

15. Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami A. Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2015 Jan; 59(1):21–28. https://doi.org/10.1007/s10384-014-0361-1 PMID: 25392274

16. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant. 2013 Mar; 48(3):452–458. https://doi.org/10.1038/bmt.2012.244 PMID: 23208313

17. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003 Jun; 23(3):288–298. PMID: 12824827

18. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003 Dec; 23(6):752–763. PMID: 14707823

19. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008 Jan; 28(1):85–93. https://doi.org/10.1097/IAE.0b013e318156777f PMID: 18185143

20. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008 Oct; 115(10):1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014 PMID: 18538401

21. Özmert E, Demirel S, Yanık Ö, Baçoğlu F. Low-fluence photodynamic therapy versus subthreshold micropulse yellow wavelength laser in the treatment of chronic central serous chorioretinopathy. J Ophthalmol. 2016; 2016:3513794. https://doi.org/10.1155/2016/3513794 PMID: 27597894

22. Koss M, Beger I, Koch F. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012 Feb; 26(2):307–314.